Marco Polo Peralta Álvarez

Author

Also Known As

Elizabeth Penn, Lucy Kingham-Page, M. Alvarez, M.P. Peralta Álvarez, M.P. Peralta-Álvarez, Marco P Peralta-Álvarez, Marco Polo Peralta Alvarez, Marco Polo Peralta Álvarez, Marco Polo Peralta-Alvarez, Marco Polo Peralta-Álvarez

Publications

10.3K

Citations

H-Index

Concepts

All Affiliations

Jenner Institute University of Oxford University of Cape Town St George's, University of London University Hospitals Bristol NHS Foundation Trust

About

Marco Polo Peralta Álvarez is an author at Jenner Institute specializing in vaccine development, vaccination, and vaccine safety.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	2.6K
2	Immunology	1	1	2.6K
3	Vaccine Development	1	1	2.6K
4	Covid-19	1	1	2.6K
5	Vaccination	1	1	2.6K

Marco Polo Peralta Álvarez

Publications

9.2K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2020	5K
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley, The Lancet VaccinationVaccine SafetyPhase 1/2Vaccine DevelopmentPreliminary Report	2020	2.6K
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2021	1.2K
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) Amy Flaxman, Natalie G. Marchevsky, Daniel Jenkin, The Lancet	2021	253
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer Óscar Arrieta, Feliciano Barrón, Zyanya Lucía Zatarain-Barrón, JAMA Oncology	2020	149
Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components Sofiya Fedosyuk, Thomas M. Merritt, Marco Polo Peralta Álvarez, Vaccine	2019	35
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial Iman Satti, Julia L. Marshall, Stephanie A. Harris, The Lancet Infectious Diseases	2024	28
Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination Julia Bitencourt, Marco Polo Peralta Álvarez, Morven Wilkie, Frontiers in Immunology	2022	19

Page 1